vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 06, 2025 Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals […]